From Renal and Urology news.
Olaparib combined with cediranib improves radiographic progression-free survival (rPFS) compared with olaparib alone in men with metastatic castration-resistant prostate cancer (mCRPC), results from a recent randomized phase 2 clinical trial suggest.
In an analysis of an intention-to-treat set of 90 patients with progressive mCRPC, median rPFS was 8.5 months for patients who received olaparib plus cediranib compared with 4.0 months among those treated with olaparib alone, Joseph W. Kim, MD, of the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and colleagues reported in the Journal of Clinical Oncology. The combination treatment was significantly associated with a 38.3% decreased risk for radiographic progression compared with olaparib alone. The combination arm had a higher incidence of grade 3-4 adverse events than the monotherapy arm (61% vs 18%).
Cediranib is a pan-vascular endothelial growth factor receptor (VEGFR) inhibitor that suppresses expression of homologous recombination repair (HRR) genes. Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor. Patients in the combination arm received olaparib 200 mg twice daily plus cediranib 30 mg once daily; patients in the olaparib-only arm received the drug at a dosage of 300 mg twice daily. The investigators examined treatment effects according to gene biomarker subgroups.
Reference
Kim JW, McKay RR, Radke MR, et al. Randomized trial of olaparib with or without cediranib for metastatic castration-resistant prostate cancer: The results from National Cancer Institute 9984. J Clin Oncol. Published online October 18, 2022. doi:10.1200/JCO.21.02947